Tumour necrosis and microvascular proliferation are associated with 9p deletion and CDKN2A alterations in 1p/19q-deleted oligodendrogliomas

Neuropathology and Applied Neurobiology

Volumn 29, Issue 5, 2003, Pages 462-471

  Godfraind, Catherine ^a   Rousseau, E ^a,b   Ruchoux, M M ^c   Scaravilli, F ^d   Vikkula, M ^b  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b DE DUVE INSTITUTE   (Belgium)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Angiogenesis; CDKN2A; Deletion; Genetic; Methylation; Microvascular proliferation; Mutation; Oligodendroglioma

Indexed keywords

ARTICLE; ASTROCYTOMA; CANCER GROWTH; CAPILLARY PROLIFERATION; CDKN2A GENE; CHROMOSOME 9P; CHROMOSOME DELETION; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE DELETION; GENE MUTATION; GENETIC ANALYSIS; GLIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; OLIGODENDROGLIOMA; PREDICTION; PRIORITY JOURNAL; SAMPLE; TUMOR; TUMOR NECROSIS; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION;

EID: 0141596005     PISSN: 03051846     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2990.2003.00484.x     Document Type: Article

References (36)

1. Kleihues P, Cavenee WK, Eds. Pathology & Genetics. Tumours of the Nervous System. Lyon: IARC Press, 2000
2. Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 1994; 145: 1175-90
3. Kraus JA, Koopmann J, Kaskel P, Maintz D, Brandner S, Schramm J, Louis DN, Wiestler OD, von Deimling A. Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol 1995; 54: 91-5
4. Maintz D, Fiedler K, Koopmann J, Rollbrocker B, Nechev S, Lenartz D, Stangl AP, Louis DN, Schramm J, Wiestler OD, von Deimling A. Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol 1997; 56: 1098-104
5. Jeuken JW, Sprenger SH, Boerman RH, von Deimling A, Teepen HL, van Overbeeke JJ, Wesseling P. Subtyping of oligo-astrocytic tumours by comparative genomic hybridization. J Pathol 2001; 194: 81-7
6. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998; 90: 1147
7. Sasaki H, Zlatescu MC, Betensky RA, Johnk LB, Cutone AN, Cairncross JG, Louis DN. Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade 'oligodendroglioma'. J Neuropathol Exp Neurol 2002; 61: 58-63
8. Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 1997; 79: 1381-93
9. Burger PC, Minn AY, Smith JS, Borell TJ, Jedlicka AE, Huntley BK, Goldthwaite PT, Jenkins RB, Feuerstein BG. Losses of chromosomal arms 1p and 19q in the diagnosis of oligodendroglioma. A study of paraffin-embedded sections. Mod Pathol 2001; 14: 842-53
10. Ruas M, Peters G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1998; 1378: F115-77
11. Bortolotto S, Chiado-Piat L, Cavalla P, Bosone I, Chio A, Mauro A, Schiffer D. CDKN2A/p16 inactivation in the prognosis of oligodendrogliomas. Int J Cancer 2000; 88: 554-7
12. Wolter M, Reifenberger J, Blaschke B, Ichimura K, Schmidt EE, Collins VP, Watanabe T, Nakamura M, Yonekawa Y, Kleihues P, Ohgaki H. Oligodendroglial tumors frequently demonstrate hypermethylation of the CDKN2A (MTS1, p16INK4a), p14ARF, and CDKN2B (MTS2, p15INK4b) tumor suppressor genes. J Neuropathol Exp Neurol 2001; 60: 1170-80
13. Watanabe T, Nakamura M, Yonekawa Y, Kleihues P, Ohgaki H. Promoter hypermethylation and homozygous deletion of the p14ARF and p16INK4a genes in oligodendrogliomas. Acta Neuropathol (Berl) 2001; 101: 185-9
14. Watanabe T, Yokoo H, Yokoo M, Yonekawa Y, Kleihues P, Ohgaki H. Concurrent inactivation of RB1 and TP53 pathways in anaplastic oligodendrogliomas. J Neuropathol Exp Neurol 2001; 60: 1181-9
15. Dong SM, Pang JC, Pooh WS, Hu J, To KF, Chang AR, Ng HK. Concurrent hypermethylation of multiple genes is associated with grade of oligodendroglial tumors. J Neuropathol Exp Neurol 2001; 60: 808-16
16. Mao L, Merlo A, Bedi G, Shapiro GI, Edwards CD, Rollins BJ, Sidransky D. A novel p16INK4A transcript. Cancer Res 1995; 55: 2995-7
17. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD, Clark WH, Jr., Tucker MA, Dracopoli NC. Germline p16 mutations in familial melanoma. Nat Genet 1994; 8: 15-21
18. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93: 9821-6
19. Esteller M, Tortola S, Toyota M, Capella G, Peinado MA, Baylin SB, Herman JG. Hypermethylation-associated inactivation of p14 (ARF) is independent of p16 (INK4a) methylation and p53 mutational status. Cancer Res 2000; 60: 129-33
20. Zhang L, Cui X, Schmitt K, Hubert R, Navidi W, Arnheim N. Whole genome amplification from a single cell: implications for genetic analysis. Proc Natl Acad Sci USA 1992; 89: 5847-51
21. Wong DJ, Barrett MT, Stoger R, Emond MJ, Reid BJ. p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas. Cancer Res 1997; 57: 2619-22
22. Burger PC, Scheithauer BW, Vogel FS. Surgical Pathology of the Nervous System and its Coverings, 4th edn. London: Churchill Livingstone, 2002
23. Graham DI, Lantos PL. Greenfields Neuropathology, 7th edn. London: Arnold, 2002
24. Ironside JW, Moss TH, Louis DN, Lowe JS, Weller RO. Diagnostic Pathology of Nervous System, 1st edn. London: Churchill Livingstone, 2002
25. von Deimling A, Louis DN, Wiestler OD. Molecular pathways in the formation of gliomas. Glia 1995; 15: 328-38
26. Louis DN, Holland EC, Cairncross JG. Glioma classification: a molecular reappraisal. Am J Pathol 2001; 159: 779-86
27. Bigner SH, Matthews MR, Rasheed BK, Wiltshire RN, Friedman HS, Friedman AH, Stenzel TT, Dawes DM, McLendon RE, Bigner DD. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. Am J Pathol 1999; 155: 375-86
28. Smith JS, Tachibana I, Lee HK, Qian J, Pohl U, Mohrenweiser HW, Borell TJ, Hosek SM, Soderberg CL, von Deimling A, Perry A, Scheithauer BW, Louis DN, Jenkins RB. Mapping of the chromosome 19 q-arm glioma tumor suppressor gene using fluorescence in situ hybridization and novel microsatellite markers. Genes Chromosomes Cancer 2000; 29: 16-25
29. Kros JM, Hop WC, Godschalk JJ, Krishnadath KK. Prognostic value of the proliferation-related antigen Ki-67 in oligodendrogliomas. Cancer 1996; 78: 1107-13
30. Harada H, Nakagawa K, Iwata S, Saito M, Kumon Y, Sakaki S, Sato K, Hamada K. Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas. Cancer Res 1999; 59: 3783-9
31. Varlet P, Guillamo JS, Nataf F, Koziak M, Beuvon F, Daumas-Duport C. Vascular endothelial growth factor expression in oligodendrogliomas: a correlative study with Sainte-Anne malignancy grade, growth fraction and patient survival. Neuropathol Appl Neurobiol 2000; 26: 379-89
32. Chaudhry IH, O'Donovan DG, Brenchley PE, Reid H, Roberts IS. Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas. Histopathology 2001; 39: 409-15
33. Christov C, Adle-Biassette H, Le Guerinel C, Natchev S, Gherardi RK. Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the vasculature of oligodendrogliomas. Neuropathol Appl Neurobiol 1998; 24: 29-35
34. Chan AS, Leung SY, Wong MP, Yuen ST, Cheung N, Fan YW, Chung LP. Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma. Am J Surg Pathol 1998; 22: 816-26
35. Alvarez JA, Baird A, Tatum A, Daucher J, Chorsky R, Gonzalez AM, Stopa EG. Localization of basic fibroblast growth factor and vascular endothelial growth factor in human glial neoplasms. Mod Pathol 1992; 5: 303-7
36. Sasaki H, Zlatescu MC, Betensky RA, Ino Y, Cairncross JG, Louis DN. PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. Am J Pathol 2001; 159: 359-67